Industry News
Life Sciences
Top stories summarized by our editors
7/30/2021

A Series C financing round produced $180 million for Deep Genomics, a startup that uses artificial intelligence to analyze genetic data, as well as discover and develop new drugs. The company plans to bring four programs into clinic in the next two years, while simultaneously boosting the company's pipeline.

Full Story:
MedCity News
7/30/2021

Smith & Nephew generated $1.3 billion in revenue during its second quarter, up 48.2% from the previous year.

Full Story:
Becker's Spine Review
More Summaries:
Smith & Nephew
7/30/2021

Dexcom generated $595.1 in sales and $62.9 million in profits during its second quarter, which ended June 30.

7/30/2021

The Jot Dx insertable cardiac monitor, which may help remotely identify cardiac arrhythmia and improve diagnosis accuracy, has been released by Abbott.

7/30/2021

European regulators have given CE mark certification to MeMed for its MeMed COVID-19 Severity tool that could help determine the risk of severe outcomes in people.

7/30/2021

The FDA has given breakthrough status designation to Biofourmis for its BiovitalsHF medical device software that is used to treat heart failure.

Full Story:
FDAnews
7/30/2021

The FDA has given 510(k) clearance to NYU Langone Health for its Genome PACT genetic test for solid tumors.

7/30/2021

European regulators have given CE-IVD mark certification to Cepheid for two PCR-based tests that detect HIV-1, its Xpert HIV-1 Qual XC and its Xpert HIV-1 Viral Load XC.

7/30/2021

Health Canada has given its approval to Luxsonic for its SieVRt, a software that would allow radiologists to use a virtual reality headset to diagnose patients remotely.

Full Story:
FDAnews
7/30/2021

Patty LaBelle is encouraging consumers to get their cancer screenings in an advertising campaign sponsored by the Community Oncologist Alliance and Cancer Care. The organizations spearheaded the campaign based on a study from Avalere Health that shows breast cancer screenings declined 85% and colon cancer screenings declined 75% during the pandemic when compared to the previous year.

Full Story:
FiercePharma